OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Current Treatment Options for Cystic Fibrosis-Related Liver Disease
Katharina Staufer
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8586-8586
Open Access | Times Cited: 27
Katharina Staufer
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8586-8586
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Cellular Mechanisms of Liver Fibrosis
Pragyan Acharya, Komal Chouhan, Sabine Weiskirchen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 179
Pragyan Acharya, Komal Chouhan, Sabine Weiskirchen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 179
Cholestatic liver diseases of genetic etiology: Advances and controversies
Samar H. Ibrahim, Binita M. Kamath, Kathleen M. Loomes, et al.
Hepatology (2022) Vol. 75, Iss. 6, pp. 1627-1646
Closed Access | Times Cited: 35
Samar H. Ibrahim, Binita M. Kamath, Kathleen M. Loomes, et al.
Hepatology (2022) Vol. 75, Iss. 6, pp. 1627-1646
Closed Access | Times Cited: 35
An Update on CFTR Modulators as New Therapies for Cystic Fibrosis
John A. King, Anna-Louise Nichols, Siân Bentley, et al.
Pediatric Drugs (2022) Vol. 24, Iss. 4, pp. 321-333
Open Access | Times Cited: 31
John A. King, Anna-Louise Nichols, Siân Bentley, et al.
Pediatric Drugs (2022) Vol. 24, Iss. 4, pp. 321-333
Open Access | Times Cited: 31
Guidelines for the Management of Cholestatic Liver Diseases (2021)
Lungen Lu
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 4, pp. 757-769
Open Access | Times Cited: 30
Lungen Lu
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 4, pp. 757-769
Open Access | Times Cited: 30
Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor
Marci Wood, Faith Babowicz, Amanda G. Kennedy, et al.
Journal of the American Pharmacists Association (2023) Vol. 63, Iss. 3, pp. 920-924
Closed Access | Times Cited: 10
Marci Wood, Faith Babowicz, Amanda G. Kennedy, et al.
Journal of the American Pharmacists Association (2023) Vol. 63, Iss. 3, pp. 920-924
Closed Access | Times Cited: 10
Resolution of portal hypertension in a patient with cystic fibrosis after treatment with CFTR modulator: A case report
Erica Loon, Joanne Billings, Nicholas Lim
Journal of Cystic Fibrosis (2025)
Closed Access
Erica Loon, Joanne Billings, Nicholas Lim
Journal of Cystic Fibrosis (2025)
Closed Access
The Multifaceted Roles of MicroRNAs in Cystic Fibrosis
Fatima Domenica Elisa De Palma, Valeria Raia, Guido Kroemer, et al.
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1102-1102
Open Access | Times Cited: 25
Fatima Domenica Elisa De Palma, Valeria Raia, Guido Kroemer, et al.
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1102-1102
Open Access | Times Cited: 25
Sotagliflozin attenuates liver associated disorders in cystic fibrosis rabbits
Xiubin Liang, Xia Hou, Mohamad Bouhamdan, et al.
JCI Insight (2024)
Open Access | Times Cited: 3
Xiubin Liang, Xia Hou, Mohamad Bouhamdan, et al.
JCI Insight (2024)
Open Access | Times Cited: 3
Cystic fibrosis associated liver disease in children
Joseph Valamparampil, Girish Gupte
World Journal of Hepatology (2021) Vol. 13, Iss. 11, pp. 1727-1742
Open Access | Times Cited: 19
Joseph Valamparampil, Girish Gupte
World Journal of Hepatology (2021) Vol. 13, Iss. 11, pp. 1727-1742
Open Access | Times Cited: 19
Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management
Dhiren Patel, Albert Shan, Stacy Mathews, et al.
Nutrients (2022) Vol. 14, Iss. 5, pp. 1028-1028
Open Access | Times Cited: 13
Dhiren Patel, Albert Shan, Stacy Mathews, et al.
Nutrients (2022) Vol. 14, Iss. 5, pp. 1028-1028
Open Access | Times Cited: 13
Single‐cell RNA sequencing of cystic fibrosis liver disease explants reveals endothelial complement activation
Mathias Declercq, Lucas Treps, Vincent Geldhof, et al.
Liver International (2024) Vol. 44, Iss. 9, pp. 2382-2395
Closed Access | Times Cited: 2
Mathias Declercq, Lucas Treps, Vincent Geldhof, et al.
Liver International (2024) Vol. 44, Iss. 9, pp. 2382-2395
Closed Access | Times Cited: 2
Evolving Nutritional Needs in Cystic Fibrosis
T. Frantzen, Sara Barsky, Geralyn LaVecchia, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1431-1431
Open Access | Times Cited: 5
T. Frantzen, Sara Barsky, Geralyn LaVecchia, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1431-1431
Open Access | Times Cited: 5
VX‐809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation
Murali K. Yanda, Liudmila Cebotaru
The FASEB Journal (2021) Vol. 35, Iss. 11
Open Access | Times Cited: 11
Murali K. Yanda, Liudmila Cebotaru
The FASEB Journal (2021) Vol. 35, Iss. 11
Open Access | Times Cited: 11
Cystic fibrosis rabbits develop spontaneous hepatobiliary lesions and CF-associated liver disease (CFLD)-like phenotypes
Qingtian Wu, Xiubin Liang, Xia Hou, et al.
PNAS Nexus (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 6
Qingtian Wu, Xiubin Liang, Xia Hou, et al.
PNAS Nexus (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 6
Cystic fibrosis liver disease in children – A review of our current understanding
Guillermo Costaguta, Natalie Patey, Fernando Álvarez
Archivos Argentinos de Pediatria (2023) Vol. 121, Iss. 4
Open Access | Times Cited: 3
Guillermo Costaguta, Natalie Patey, Fernando Álvarez
Archivos Argentinos de Pediatria (2023) Vol. 121, Iss. 4
Open Access | Times Cited: 3
Liver magnetic resonance elastography and fat fraction in pediatric patients with cystic fibrosis versus healthy children
Aziz Anıl Tan, Duygu Demirtaş, Hayriye Hızarcıoğlu Gülşen, et al.
Pediatric Radiology (2023) Vol. 54, Iss. 2, pp. 250-259
Closed Access | Times Cited: 2
Aziz Anıl Tan, Duygu Demirtaş, Hayriye Hızarcıoğlu Gülşen, et al.
Pediatric Radiology (2023) Vol. 54, Iss. 2, pp. 250-259
Closed Access | Times Cited: 2
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis
Andrew Burke, Daniel J. Smith, Chris Coulter, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 9, pp. 1081-1102
Closed Access | Times Cited: 5
Andrew Burke, Daniel J. Smith, Chris Coulter, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 9, pp. 1081-1102
Closed Access | Times Cited: 5
Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis
John P. ONeill, Cathal S Clifford, Niamh Nolan, et al.
Irish Journal of Medical Science (1971 -) (2022) Vol. 192, Iss. 4, pp. 1657-1660
Closed Access | Times Cited: 3
John P. ONeill, Cathal S Clifford, Niamh Nolan, et al.
Irish Journal of Medical Science (1971 -) (2022) Vol. 192, Iss. 4, pp. 1657-1660
Closed Access | Times Cited: 3
Risk factors for more rapid progression of severe liver fibrosis in children with cystic fibrosis‐related liver disease: A multi‐center study validated by liver biopsy
Shruti Sakhuja, Heather Staples, Charles G. Minard, et al.
Liver International (2023) Vol. 43, Iss. 6, pp. 1277-1286
Closed Access | Times Cited: 1
Shruti Sakhuja, Heather Staples, Charles G. Minard, et al.
Liver International (2023) Vol. 43, Iss. 6, pp. 1277-1286
Closed Access | Times Cited: 1
Diagnosis, Management, and Prognosis of Cystic Fibrosis-Related Liver Disease in Children
Dana-Teodora Anton-Păduraru, Alice Azoicăi, Felicia Trofin, et al.
Diagnostics (2024) Vol. 14, Iss. 5, pp. 538-538
Open Access
Dana-Teodora Anton-Păduraru, Alice Azoicăi, Felicia Trofin, et al.
Diagnostics (2024) Vol. 14, Iss. 5, pp. 538-538
Open Access
Modern possibilities for preventing the formation of liver fibrosis in children: the basics of preventive pediatric hepatology
K. I. Grigoryev, Л. А. Харитонова
Experimental and Clinical Gastroenterology (2024), Iss. 7, pp. 107-118
Open Access
K. I. Grigoryev, Л. А. Харитонова
Experimental and Clinical Gastroenterology (2024), Iss. 7, pp. 107-118
Open Access
Acute Liver Failure Triggered by Therapeutic Dose of Acetaminophen in a Patient with Cystic Fibrosis
Adam Goodman, Emily E. Grenn, F. Koller, et al.
The American Surgeon (2021) Vol. 89, Iss. 4, pp. 767-768
Open Access | Times Cited: 2
Adam Goodman, Emily E. Grenn, F. Koller, et al.
The American Surgeon (2021) Vol. 89, Iss. 4, pp. 767-768
Open Access | Times Cited: 2
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Wenkang Gao, Zhonglin Li, Huikuan Chu, et al.
(2022), pp. 81-111
Closed Access | Times Cited: 1
Wenkang Gao, Zhonglin Li, Huikuan Chu, et al.
(2022), pp. 81-111
Closed Access | Times Cited: 1
Enfermedad hepática en la fibrosis quística pediátrica. Una revisión de los conocimientos actuales
Archivos Argentinos de Pediatria (2023) Vol. 121, Iss. 4
Open Access
Archivos Argentinos de Pediatria (2023) Vol. 121, Iss. 4
Open Access
Liver fi brosis formation in children: the basics of preventive pediatric hepatology
Л. А. Харитонова, K. I. Grigorуev
Experimental and Clinical Gastroenterology (2023) Vol. 1, Iss. 1, pp. 5-17
Open Access
Л. А. Харитонова, K. I. Grigorуev
Experimental and Clinical Gastroenterology (2023) Vol. 1, Iss. 1, pp. 5-17
Open Access
